title: Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
abstract: OBJECTIVE
  Although the taxanes represent the most active agents for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC), most patients eventually progress while receiving taxane-based treatments. No agents are approved for second-line therapy in HRPC, but common standard practice for the oncologists is to treat patients also after docetaxel failure.
  
  
  METHODS
  Twenty highly pretreated patients with HRPC received bevacizumab (10mg/kg) and docetaxel (60mg/m(2)) every 3 wk. All patients had bone metastases and eight had measurable lesions.
  
  
  RESULTS
  Eleven patients (55%) had major prostate-specific antigen (PSA) responses, and 3 (37.5%) had objective responses. Seven major PSA responses were recorded in the same patients who had reported a >50% PSA decrease after first-line docetaxel. However, four major PSA responses were observed in patients previously nonresponsive to docetaxel alone. The treatment was well tolerated.
  
  
  CONCLUSIONS
  Our results show that the combination of bevacizumab and docetaxel is active and well tolerated. Continued investigation of bevacizumab with cytotoxic chemotherapy is warranted in HRPC.
authors.affiliation: Department of Clinical and Molecular Oncology, Federico II University, Naples, Italy. giuseppedilorenzocol@hotmail.com
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Di Lorenzo
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
authors.forename: Sophie D
authors.initials: SD
authors.lastname: Fossa
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Mirone
authors.forename: Riccardo
authors.initials: R
authors.lastname: Autorino
authors.forename: Nicola
authors.initials: N
authors.lastname: Longo
authors.forename: Ciro
authors.initials: C
authors.lastname: Imbimbo
authors.forename: Sisto
authors.initials: S
authors.lastname: Perdonà
authors.forename: Antonio
authors.initials: A
authors.lastname: Giordano
authors.forename: Mario
authors.initials: M
authors.lastname: Giuliano
authors.forename: Roberto
authors.initials: R
authors.lastname: Labianca
authors.forename: Sabino
authors.initials: S
authors.lastname: De Placido
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000068258:Bevacizumab; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011838:Radiation-Sensitizing Agents; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D006728:Hormones; D011838:Radiation-Sensitizing Agents; D043823:Taxoids; D042461:Vascular Endothelial Growth Factor A; D000077143:Docetaxel; D000068258:Bevacizumab